Adalimumab biosimilar (Shanghai Maitaiyabo Biotech)

阿达木单抗生物类似药（上海迈泰亚博生物）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAdalimumab biosimilar (Shanghai Maitaiyabo Biotech)

Drug Alias Name重组抗TNFα全人源单抗（上海迈泰亚博生物）Recombinant human anti-tumour necrosis factor alpha (TNF-α) monoclonal antibody (Shanghai Maitaiyabo Biotech)重组抗肿瘤坏死因子-α全人源单抗（上海迈泰亚博生物）阿达木单抗生物仿制药（上海迈泰亚博生物）

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human

Mechanisms of ActionTumor necrosis factor α inhibitors

TargetsTumor necrosis factor α

Therapy Area/IndicationsArthritis, Rheumatoid

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (IND)

Highest Status in ChinaPending

Originator CompaniesShanghai Maitai Yabo Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesShanghai Maitai Yabo Biotechnology Co Ltd

Active IndicationsN/A

Inactive IndicationsArthritis, Rheumatoid

Other Information

ATC CodeL04AB04